CHP-MAGE-A4癌症疫苗接种后CD4CD25Foxp3调节性T细胞频率的临床意义
Clinical Implications of CD4CD25Foxp3Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination.
作者信息
Wada Masataka, Tsuchikawa Takahiro, Kyogoku Noriaki, Abiko Takehiro, Miyauchi Kengo, Takeuchi Shintaro, Kuwatani Toshihiko, Shichinohe Toshiaki, Miyahara Yoshihiro, Kageyama Shinichi, Ikeda Hiroaki, Shiku Hiroshi, Hirano Satoshi
机构信息
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan
出版信息
Anticancer Res. 2018 Mar;38(3):1435-1444. doi: 10.21873/anticanres.12368.
BACKGROUND/AIM: The aim of this study was to explore whether the treatment effect or immune response to a cancer vaccine can be predicted by the percentage of CD4CD25Foxp3 regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) after vaccination.
PATIENTS AND METHODS
Sixteen patients (9 men, 7 women; median age 61.5 years) enrolled in the CHP-MAGE-A4 cancer vaccine clinical trial who had a fixed dose (300 μg of CHP-MAGE-A4 cancer vaccine and 0.5 Klinische Einheit (KE) of OK432 and received at least four vaccinations were investigated. Safety, immune response, and clinical effects were assessed before and after the cancer vaccination.
RESULTS
Treg ratios that remained low both before and after vaccination were associated with a good prognosis, and a low Treg/CD4 lymphocyte ratio 7-weeks after the initial vaccination was correlated with a better prognosis.
CONCLUSION
The Treg ratio following vaccination appears to have some utility for predicting patient prognosis.
背景/目的：本研究旨在探讨接种疫苗后外周血单个核细胞（PBMC）中CD4CD25Foxp3调节性T细胞（Tregs）的百分比是否可预测癌症疫苗的治疗效果或免疫反应。
患者与方法
对16名患者（9名男性，7名女性；中位年龄61.5岁）进行了研究，这些患者参加了CHP-MAGE-A4癌症疫苗临床试验，接受固定剂量（300μg CHP-MAGE-A4癌症疫苗和0.5 Klinische Einheit (KE) 的OK432）且至少接种了四次疫苗。在癌症疫苗接种前后评估安全性、免疫反应和临床效果。
结果
接种前后Treg比例均保持较低水平与良好预后相关，初次接种7周后较低的Treg/CD4淋巴细胞比例与较好的预后相关。
结论
接种疫苗后的Treg比例似乎对预测患者预后有一定作用。
Zotero 插件